Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON
Objective We assessed adverse events and changes in forced vital capacity (FVC) in patients treated with open-label nintedanib over 148 weeks of SENSCIS-ON, the extension of the SENSCIS trial.Methods Adverse events and changes in FVC over 148 weeks of SENSCIS-ON were assessed in patients who receive...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMJ Publishing Group
2025-02-01
|
| سلاسل: | RMD Open |
| الوصول للمادة أونلاين: | https://rmdopen.bmj.com/content/11/1/e005086.full |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|